1. ALS Genetics: Gains, Losses, and Implications for Future Therapies
- Author
-
Garam Kim, Eduardo Tassoni-Tsuchida, X. Rosa Ma, Aaron D. Gitler, and Olivia Gautier
- Subjects
0301 basic medicine ,SOD1 ,TARDBP ,Article ,03 medical and health sciences ,Superoxide Dismutase-1 ,0302 clinical medicine ,TANK-binding kinase 1 ,Loss of Function Mutation ,C9orf72 ,Animals ,Humans ,Medicine ,Amyotrophic lateral sclerosis ,Loss function ,C9orf72 Protein ,business.industry ,General Neuroscience ,Amyotrophic Lateral Sclerosis ,Genetic Therapy ,medicine.disease ,030104 developmental biology ,Gain of function ,Gain of Function Mutation ,business ,Neuroscience ,030217 neurology & neurosurgery ,Forecasting - Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder caused by the loss of motor neurons from the brain and spinal cord. The ALS community has made remarkable strides over three decades by identifying novel familial mutations, generating animal models, elucidating molecular mechanisms, and ultimately developing promising new therapeutic approaches. Some of these approaches reduce the expression of mutant genes and are in human clinical trials, highlighting the need to carefully consider the normal functions of these genes and potential contribution of gene loss-of-function to ALS. Here, we highlight known loss-of-function mechanisms underlying ALS, potential consequences of lowering levels of gene products, and the need to consider both gain and loss of function to develop safe and effective therapeutic strategies.
- Published
- 2020